BCHE and Alzheimer disease: The M1 receptor in particular, with its high expression in memory centers and procognitive properties, has been proposed as a target for treating memory loss in AD that would avoid the dose-limiting, adverse responses associated with current clinically approved cholinesterase inhibitors (24, 25).